Amann F, Hefner G, Cremer-Schaeffer P, Gründer G, Häuser W, Hart XM, Petzke F, Zernig G, Havemann-Reinecke U. Therapeutic Drug Monitoring of Cannabinoids: Therapeutic Reference Ranges for Delta-9-tetrahydrocannabinol in Medical Cannabis, Nabiximols, Dronabinol and Nabilone. Pharmacopsychiatry. 2026 Jun 10. [Epub ahead of print]
Barthel H, Brendel M, Albert N, Boecker H, Bouter C, Brumberg J, Buchert R, la Fougère C, Gründer G, Hesse S, Kuwert T, Lange C, Langen KJ, Lohmann P, Meyer PT, Miederer I, Neumaier B, Rominger A, Schreckenberger M, Schulz JB, Yakushev I, Drzezga A. Updated Procedure Guideline of the German Society of Nuclear Medicine for Amyloid Brain PET Imaging 3.0. Nuklearmedizin. 2026 65(3):223-235.
Buchert R, Meyer PT, Albert NL, Barthel H, Boecker H, Bouter C, Brendel M, Brumberg J, Coenen HH, Drzezga A, Gründer G, Grünwald F, Hesse S, Kuwert T, Fougère C, Lange C, Lohmann P, Menzel C, Miederer I, Neumaier B, Rominger A, Schmitz CN, Schreckenberger M, Yakushev I, Kranert WT, Working Group Nuclear Neuroimaging of the German Society of Nuclear Medicine Working Group Nuclear Neuroimaging of the German Society of Nuclear Medicine. German Society of Nuclear Medicine procedure guideline for brain perfusion SPECT using 99mTc-labelled radiopharmaceuticals (09/2025). Nuklearmedizin. 2026 Jun 2. [Epub ahead of print]
Gründer G, Bielen H, Broich K, Lipinski S, Rinke W, Röseler A, Schuier M, von der Goltz C, Weiland M, Meyer-Lindenberg A, Reif A. [Psychotropic drug research in Germany: challenges of early benefit assessment and precision psychiatry]. Nervenarzt. 2026 Jul 6. [Epub ahead of print]
Gründer G, Mertens L, Jungaberle A, Jungaberle H, Spangemacher M. Compassionate use of psilocybin for treatment-resistant depression in Germany. Lancet Psychiatry. 2026 13(2):91-93. Epub 2025 Sep 18.
Hart XM, Gründer G, Hiemke C, Adamovic I, Amann F, Baumann P, Bergemann N, Brandt C, Clement HW, Conca A, Deckert J, Dietmaier O, Eckermann G, Egberts K, Endres K, Erlacher N, Fekete S, Ferrea S, Florio V, Gerlach M, Haen E, Hahn M, Havemann-Reinecke U, Hefner G, Jost WH, Kuzin M, Laux G, Leucht S, Maniscalco I, Menke A, Messer T, Moessner R, Müller DJ, Müller T, Paulzen M, Petri H, Pfeifer P, Pfuhlmann B, Riederer P, Roll SC, Scherf-Clavel M, Schwarz M, Steimer W, Stingl JC, Toto S, Ulrich S, Zernig G, Zurek G, Unterecker S, Schoretsanitis G. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2026 - Pharmacokinetic, pharmacogenetic and clinical aspects. Pharmacopsychiatry. 2026 Jul 2. [Epub ahead of print]
Hart XM, Hirjak D, Eap CB, Eichentopf L, Fritze S, Lense XM, Scharf D, Schilling C, Schwind N, Post P, Wesner K, Gründer G. High Clozapine Serum Levels Do Not Improve Response: An Observational Study in Patients with Schizophrenia Treated with Clozapine in a Naturalistic Setting. Pharmacopsychiatry. 2026 May 20. [Epub ahead of print]
Mertens L, Betzler F, Brand M, Evens R, Jungaberle A, Jungaberle H, Kärtner L, Majic T, Schmitz C, Ströhle A, Scharf D, Spangemacher M, Wolff M, Assadi Z, Bahri S, Becher L, Färber LV, Harder H, Kirchen N, Kulakova E, Kunz LC, Meijer A, Rohrmoser B, Wellek S, Berger M, Koslowski M, Gründer G. Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression (EPIsoDE): 6- and 12-Month Naturalistic Follow-Up of a Phase 2b Trial. Psychother Psychosom. 2026 May 27. [Epub ahead of print] :1-28.
Mertens L, Koslowski M, Betzler F, Brand M, Evens R, Kärtner L, Jungaberle A, Jungaberle H, Majic T, Schmitz C, Ströhle A, Scharf D, Spangemacher M, Wolff M, Assadi Z, Bahri S, Becher L, Färber LV, Kirchen N, Kulakova E, Kunz L, Meijer A, Rohrmoser B, Wellek S, Berger M, Gründer G. Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial. JAMA Psychiatry. 2026 83(5):448-460. Epub 2026 Mar 18.
Mlynek E, Tan X, Lammertz SE, Schaffrath S, Gründer G, Schneider F, Frodl T, Mathiak K, Gaebler AJ. Disturbed Functional Connectivity Between Anterior Default Mode and Sensory Processing Regions Is Linked to Peripheral Inflammatory Markers and Psychopathology in Schizophrenia. Schizophr Bull. 2026 52(1):sbaf048. Epub 2025 Apr 23.
Pedraz-Petrozzi B, Marszalek-Grabska M, Fornal E, Wielgosz A, Stachniuk A, Marzec P, Neumann E, Riedinger E, Gilles M, Gründer G, Danyeli LV, Sen ZD, Walter M, Sartorius A, Spangemacher M, Reinwald JR. Kynurenine pathway profiles as markers of ketamine response in treatment-resistant depression. Brain Behav Immun. 2026 Jul 5. [Epub ahead of print] 138:106889.